NovaBay Pharmaceuticals, Inc, mid-stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections without causing resistance, has entered into an agreement with Galderma SA to develop and commercialize NovaBay's novel proprietary Aganocide compounds.

MDRNA, Inc. has entered into a licensing agreement with Novartis for MDRNA's liposomal technology platform for siRNA delivery. MDRNA will receive $7.25 million in upfront fees for the non-exclusive license. Additionally, the companies have entered into a separate agreement, which provides Novartis with an exclusive period to negotiate a research and development collaboration and broader licensing rights related to MDRNA's RNAi drug delivery platform. Terms of this separate agreement were not disclosed.

Medivation, Inc has received written permission from the US Food and Drug Administration (FDA) to begin a pivotal phase-3 trial of MDV3100, its novel androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed docetaxel-based chemotherapy.

The ongoing New Millennium Indian Technology Leadership Initiative (NMTTLI), being implemented in public-private partnership mode, has scored a number of achievements in different sectors including pharma and biotechnology so far, by developing many new molecules and taking some of them into various stages of trials.